Products

Human cytomegalovirus cDNA and Antigen

Cat#

Product Name

Swiss Prot#

Size

Price (US$)

Order

PN0822

Recombinant Protein-Human cytomegalovirus Envelope glycoprotein H (a.a.100 to 450)

A8T7F0

100 µg

1195

Order

PN0823

Recombinant Protein-Human cytomegalovirus Immediate early transcriptional regulator (a.a.51 to 491)

B8Y6S4

100 µg

1195

Order

PN0824

Recombinant Protein-Human cytomegalovirus Envelope glycoprotein US27 (a.a.21 to 362)

B8YEI5

100 µg

1195

Order

PN0825

Recombinant Protein-Human cytomegalovirus 72 kDa immediate-early 1 protein (a.a.51 to 491)

C7E3P2

100 µg

1195

Order

PN0826

Recombinant Protein-Human cytomegalovirus Envelope glycoprotein O (a.a.34 to 462)

C8CFB2

100 µg

1195

Order

PN0827

Recombinant Protein-Human cytomegalovirus Capsid scaffold protein (a.a.21 to 372)

C8CFT5

100 µg

1195

Order

PN0828

Recombinant Protein-Human cytomegalovirus Major immediate-early antigen (a.a.21 to 128)

Q68084

100 µg

1195

Order

PN0829

Recombinant Protein-Human cytomegalovirus Pp34 (a.a.21 to 268)

Q69214

100 µg

1195

Order

PN0830

Recombinant Protein-Human cytomegalovirus Pp43 (a.a.21 to 358)

Q69215

100 µg

1195

Order

PN0831

Recombinant Protein-Human cytomegalovirus Surface antigen (a.a.18 to 117)

Q9PZP0

100 µg

1195

Order

PN0832

Recombinant Protein-Human cytomegalovirus Envelope glycoprotein B (a.a.461 to 907)

P13201

100 µg

1195

Order

PN0833

Recombinant Protein-Human cytomegalovirus 55 kDa immediate-early protein 1 (a.a.21 to 491)

P03169

100 µg

1195

Order

RPN0822

cDNA-Human cytomegalovirus Envelope glycoprotein H (a.a.100 to 450)

A8T7F0

2 µg

1750

Order

RPN0823

cDNA-Human cytomegalovirus Immediate early transcriptional regulator (a.a.51 to 491)

B8Y6S4

2 µg

2200

Order

RPN0824

cDNA-Human cytomegalovirus Envelope glycoprotein US27 (a.a.21 to 362)

B8YEI5

2 µg

1705

Order

RPN0825

cDNA-Human cytomegalovirus 72 kDa immediate-early 1 protein (a.a.51 to 491)

C7E3P2

2 µg

2200

Order

RPN0826

cDNA-Human cytomegalovirus Envelope glycoprotein O (a.a.34 to 462)

C8CFB2

2 µg

2140

Order

RPN0827

cDNA-Human cytomegalovirus Capsid scaffold protein (a.a.21 to 372)

C8CFT5

2 µg

1755

Order

RPN0828

cDNA-Human cytomegalovirus Major immediate-early antigen (a.a.21 to 128)

Q68084

2 µg

535

Order

RPN0829

cDNA-Human cytomegalovirus Pp34 (a.a.21 to 268)

Q69214

2 µg

1235

Order

RPN0830

cDNA-Human cytomegalovirus Pp43 (a.a.21 to 358)

Q69215

2 µg

1685

Order

RPN0831

cDNA-Human cytomegalovirus Surface antigen (a.a.18 to 117)

Q9PZP0

2 µg

800

Order

RPN0832

cDNA-Human cytomegalovirus Envelope glycoprotein B (a.a.461 to 907)

P13201

2 µg

2230

Order

RPN0833

cDNA-Human cytomegalovirus 55 kDa immediate-early protein 1 (a.a.21 to 491)

P03169

2 µg

2350

Order

Human cytomegalovirus cDNA and recombinant antigen

  • Codon-optimized cDNA is cloned into E. coli expression vector with 6x His-tag at N-terminus and ready-to-use for recombinant protein production.
  • Recombinant protein applications: Western Blot may be used for other applications determined by the user.
  • Protein Purity: >90%, as determined by SDS-PAGE under reducing conditions.
  • Protein Activity: N/A
  • Protein Tag:  Contains A 6x histidine tag at N-terminus.
  • Protein Formulation: Liquid
  • Source: Produced from E. coli

Human Cytomegalovirus (HCMV) is a type of herpes virus that is commonly found in the human population. It is usually transmitted through close contact with bodily fluids such as saliva, urine, semen and breast milk. Most healthy people have no symptoms or only mild symptoms, but HCMV can cause serious health problems in people with weakened immune systems, such as organ transplant recipients and people with HIV/AIDS. HCMV can also cause birth defects in babies infected during pregnancy. There is currently no cure for HCMV, but antiviral drugs can help manage the symptoms.

Human Cytomegalovirus (HCMV) antigen refers to any protein or substance found in or produced by the HCMV virus. These antigens are used in diagnostic tests to identify the presence of HCMV in a person’s blood or body fluids. The detection of HCMV antigens can also help monitor the effectiveness of antiviral therapy in people with HCMV infections. Additionally, HCMV antigens are being studied for their potential use in vaccine development to prevent HCMV infections.

The Human Cytomegalovirus (HCMV) genome is the complete set of genetic information contained in the HCMV virus. The HCMV genome is composed of a double-stranded DNA molecule and is approximately 235 kilobases in length. The genome of HCMV encodes a large number of genes, many of which are involved in virus replication and evasion of the host immune response. The study of the HCMV genome has provided important insights into the biology of the virus and has been instrumental in the development of antiviral drugs and vaccines. Here are some key proteins and antigens of HCMV:

Envelope glycoproteins (H, O, US27, and B): These glycoproteins are important for HCMV entry into host cells and evasion of the immune system. They can interact with host cell receptors and modulate host immune responses.

Immediate early transcriptional regulator and immediate-early 1 protein: These proteins are involved in the regulation of viral gene expression and replication. They can activate or repress the transcription of viral genes and play a crucial role in the establishment of HCMV infection.

Capsid scaffold protein: This protein is involved in the assembly of HCMV virions. It interacts with viral DNA and helps to package it into the capsid.

Major immediate-early antigen: This is one of the earliest and most abundantly expressed viral antigens during HCMV infection. It is involved in the regulation of viral gene expression and replication.

Pp34 and Pp43: These are viral phosphoproteins that are important for HCMV replication. They can interact with host cell proteins and modulate host signaling pathways.

Surface antigen: This is a viral antigen that is expressed on the surface of infected cells. It can be used as a diagnostic marker for HCMV infection.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

Welcome to BitClone

Magnetic Beads Make Things Simple